2022-04-012023-03-312023-03-31false07561547EASTGATE DENTAL SURGERY LTD2024-01-15iso4217:GBPxbrli:pure075615472022-04-01075615472023-03-31075615472022-04-012023-03-31075615472021-04-01075615472022-03-31075615472021-04-012022-03-3107561547bus:SmallEntities2022-04-012023-03-3107561547bus:AuditExempt-NoAccountantsReport2022-04-012023-03-3107561547bus:FullAccounts2022-04-012023-03-3107561547bus:PrivateLimitedCompanyLtd2022-04-012023-03-3107561547core:WithinOneYear2023-03-3107561547core:AfterOneYear2023-03-3107561547core:WithinOneYear2022-03-3107561547core:AfterOneYear2022-03-3107561547core:ShareCapital2023-03-3107561547core:SharePremium2023-03-3107561547core:RevaluationReserve2023-03-3107561547core:OtherReservesSubtotal2023-03-3107561547core:RetainedEarningsAccumulatedLosses2023-03-3107561547core:ShareCapital2022-03-3107561547core:SharePremium2022-03-3107561547core:RevaluationReserve2022-03-3107561547core:OtherReservesSubtotal2022-03-3107561547core:RetainedEarningsAccumulatedLosses2022-03-3107561547core:LandBuildings2023-03-3107561547core:PlantMachinery2023-03-3107561547core:Vehicles2023-03-3107561547core:FurnitureFittings2023-03-3107561547core:OfficeEquipment2023-03-3107561547core:NetGoodwill2023-03-3107561547core:IntangibleAssetsOtherThanGoodwill2023-03-3107561547core:ListedExchangeTraded2023-03-3107561547core:UnlistedNon-exchangeTraded2023-03-3107561547core:LandBuildings2022-03-3107561547core:PlantMachinery2022-03-3107561547core:Vehicles2022-03-3107561547core:FurnitureFittings2022-03-3107561547core:OfficeEquipment2022-03-3107561547core:NetGoodwill2022-03-3107561547core:IntangibleAssetsOtherThanGoodwill2022-03-3107561547core:ListedExchangeTraded2022-03-3107561547core:UnlistedNon-exchangeTraded2022-03-3107561547core:LandBuildings2022-04-012023-03-3107561547core:PlantMachinery2022-04-012023-03-3107561547core:Vehicles2022-04-012023-03-3107561547core:FurnitureFittings2022-04-012023-03-3107561547core:OfficeEquipment2022-04-012023-03-3107561547core:NetGoodwill2022-04-012023-03-3107561547core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3107561547core:ListedExchangeTraded2022-04-012023-03-3107561547core:UnlistedNon-exchangeTraded2022-04-012023-03-3107561547core:MoreThanFiveYears2022-04-012023-03-3107561547core:Non-currentFinancialInstruments2023-03-3107561547core:Non-currentFinancialInstruments2022-03-3107561547dpl:CostSales2022-04-012023-03-3107561547dpl:DistributionCosts2022-04-012023-03-3107561547core:LandBuildings2022-04-012023-03-3107561547core:PlantMachinery2022-04-012023-03-3107561547core:Vehicles2022-04-012023-03-3107561547core:FurnitureFittings2022-04-012023-03-3107561547core:OfficeEquipment2022-04-012023-03-3107561547dpl:AdministrativeExpenses2022-04-012023-03-3107561547core:NetGoodwill2022-04-012023-03-3107561547core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3107561547dpl:GroupUndertakings2022-04-012023-03-3107561547dpl:ParticipatingInterests2022-04-012023-03-3107561547dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3107561547core:ListedExchangeTraded2022-04-012023-03-3107561547dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3107561547core:UnlistedNon-exchangeTraded2022-04-012023-03-3107561547dpl:CostSales2021-04-012022-03-3107561547dpl:DistributionCosts2021-04-012022-03-3107561547core:LandBuildings2021-04-012022-03-3107561547core:PlantMachinery2021-04-012022-03-3107561547core:Vehicles2021-04-012022-03-3107561547core:FurnitureFittings2021-04-012022-03-3107561547core:OfficeEquipment2021-04-012022-03-3107561547dpl:AdministrativeExpenses2021-04-012022-03-3107561547core:NetGoodwill2021-04-012022-03-3107561547core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3107561547dpl:GroupUndertakings2021-04-012022-03-3107561547dpl:ParticipatingInterests2021-04-012022-03-3107561547dpl:GroupUndertakingscore:ListedExchangeTraded2021-04-012022-03-3107561547core:ListedExchangeTraded2021-04-012022-03-3107561547dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-04-012022-03-3107561547core:UnlistedNon-exchangeTraded2021-04-012022-03-3107561547core:NetGoodwill2023-03-3107561547core:IntangibleAssetsOtherThanGoodwill2023-03-3107561547core:LandBuildings2023-03-3107561547core:PlantMachinery2023-03-3107561547core:Vehicles2023-03-3107561547core:FurnitureFittings2023-03-3107561547core:OfficeEquipment2023-03-3107561547core:AfterOneYear2023-03-3107561547core:WithinOneYear2023-03-3107561547core:ListedExchangeTraded2023-03-3107561547core:UnlistedNon-exchangeTraded2023-03-3107561547core:ShareCapital2023-03-3107561547core:SharePremium2023-03-3107561547core:RevaluationReserve2023-03-3107561547core:OtherReservesSubtotal2023-03-3107561547core:RetainedEarningsAccumulatedLosses2023-03-3107561547core:NetGoodwill2022-03-3107561547core:IntangibleAssetsOtherThanGoodwill2022-03-3107561547core:LandBuildings2022-03-3107561547core:PlantMachinery2022-03-3107561547core:Vehicles2022-03-3107561547core:FurnitureFittings2022-03-3107561547core:OfficeEquipment2022-03-3107561547core:AfterOneYear2022-03-3107561547core:WithinOneYear2022-03-3107561547core:ListedExchangeTraded2022-03-3107561547core:UnlistedNon-exchangeTraded2022-03-3107561547core:ShareCapital2022-03-3107561547core:SharePremium2022-03-3107561547core:RevaluationReserve2022-03-3107561547core:OtherReservesSubtotal2022-03-3107561547core:RetainedEarningsAccumulatedLosses2022-03-3107561547core:NetGoodwill2021-04-0107561547core:IntangibleAssetsOtherThanGoodwill2021-04-0107561547core:LandBuildings2021-04-0107561547core:PlantMachinery2021-04-0107561547core:Vehicles2021-04-0107561547core:FurnitureFittings2021-04-0107561547core:OfficeEquipment2021-04-0107561547core:AfterOneYear2021-04-0107561547core:WithinOneYear2021-04-0107561547core:ListedExchangeTraded2021-04-0107561547core:UnlistedNon-exchangeTraded2021-04-0107561547core:ShareCapital2021-04-0107561547core:SharePremium2021-04-0107561547core:RevaluationReserve2021-04-0107561547core:OtherReservesSubtotal2021-04-0107561547core:RetainedEarningsAccumulatedLosses2021-04-0107561547core:AfterOneYear2022-04-012023-03-3107561547core:WithinOneYear2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:CostValuation2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3107561547core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3107561547core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3107561547core:Non-currentFinancialInstrumentscore:CostValuation2022-03-3107561547core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-3107561547core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-3107561547core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-3107561547core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-3107561547core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-3107561547core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-3107561547core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-3107561547core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-3107561547bus:Director12022-04-012023-03-3107561547core:FurnitureFittingsToolsEquipment2022-03-3107561547core:FurnitureFittingsToolsEquipment2022-04-012023-03-3107561547core:FurnitureFittingsToolsEquipment2023-03-31

EASTGATE DENTAL SURGERY LTD

Registered Number
07561547
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2023

EASTGATE DENTAL SURGERY LTD
Company Information
for the year from 1 April 2022 to 31 March 2023

Director

HEMATHILAKA, Hetti Pathirage Udara Lakruwan

Registered Address

29 Eastgate Street
Aberystwyth
SY23 2AR

Registered Number

07561547 (England and Wales)
EASTGATE DENTAL SURGERY LTD
Statement of Financial Position
31 March 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets8131,53788,383
131,53788,383
Current assets
Stocks1019,55019,550
Debtors11190,561213,337
Cash at bank and on hand876,547584,719
1,086,658817,606
Creditors amounts falling due within one year12(147,514)(148,825)
Net current assets (liabilities)939,144668,781
Total assets less current liabilities1,070,681757,164
Creditors amounts falling due after one year13(46,447)(63,490)
Provisions for liabilities15(24,992)(16,793)
Net assets999,242676,881
Capital and reserves
Called up share capital1,0001,000
Profit and loss account998,242675,881
Shareholders' funds999,242676,881
The financial statements were approved and authorised for issue by the Director on 15 January 2024, and are signed on its behalf by:
HEMATHILAKA, Hetti Pathirage Udara Lakruwan
Director
Registered Company No. 07561547
EASTGATE DENTAL SURGERY LTD
Notes to the Financial Statements
for the year ended 31 March 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
These financial statements have been prepared in compliance with FRS 102 Section 1A, The Financial Reporting Standard applicable in the UK and Republic of Ireland.
3.Principal activities
The principal activity of the company during the year was dentistry.
4.Basis of measurement used in financial statements
The financial statements have been prepared on the historical cost basis.
5.Accounting policies
Functional and presentation currency policy
The financial statements are presented in sterling, which is the functional currency of the entity.
Property, plant and equipment policy
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Impairment of fixed assets A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. Depreciation Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Reducing balance (%)
Plant and machinery20
Fixtures and fittings20
Office Equipment20
Intangible assets policy
Goodwill Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight-line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years. Amortisation Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows: Goodwill - 10% straight line f there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Stocks policy
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all cost of purchase, cost of conversion and other costs incurred in bringing the stock to its present location and condition.
Revenue recognition policy
The revenue shown in the profit and loss account represents income receivable from dental treatments carried out during the period. Revenue in respect of dental treatment uncompleted at the year end date is recognised by reference to the state of completion.
Taxation policy
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amount of tax expected to pay or recover using the tax rates and laws that have been enacted, or substantively enacted, at the reporting date.
Deferred tax policy
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted, or substantively enacted, by the reporting date that are expected to apply to the reversal of the timing difference.
Leases policy
Assets held under finance leases and hire purchase contracts are recognised in the statement of financial position as assets and liabilities at the lower of the fair value of the assets and the present value of the minimum lease payments, which is determined at the inception of the lease term. Any initial direct costs of the lease are added to the amount recognised as an asset. Lease payments are apportioned between the finance charges and reduction of the outstanding lease liability using the effective interest method. Finance charges are allocated to each period so as to produce a constant rate of interest on the remaining balance of the liability. Operating leases Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
Valuation of financial instruments policy
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Going concern
In March 2020 the UK was impacted by the outbreak of Covid-19. The Government imposed significant restrictions at that time in an effort to manage the spread of the virus which resulted in the company having to review and change its working practices to ensure compliance with these restrictions. More latterly, the UK economy has been impacted by rising inflation, interest rates and energy costs, exacerbated by the war in Ukraine. All these matters have impacted the company's trading results to a a greater or lesser extent. At the date of signing these financial statements, the directors have considered the effect of these matters on the company with the information available to it and do not believe that it will affect the ability of the company to continue to trade for the foreseeable future. On this basis, the directors have prepared these financial statements on a going concern basis.
6.Employee information

20232022
Average number of employees during the year1013
7.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 April 22200,000200,000
At 31 March 23200,000200,000
Amortisation and impairment
At 01 April 22200,000200,000
At 31 March 23200,000200,000
Net book value
At 31 March 23--
At 31 March 22--
8.Property, plant and equipment

Plant & machinery

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 April 22174,0128,80118,480201,293
Additions20,54053,0002,49876,038
At 31 March 23194,55261,80120,978277,331
Depreciation and impairment
At 01 April 2296,5027,9008,508112,910
Charge for year19,61010,7802,49432,884
At 31 March 23116,11218,68011,002145,794
Net book value
At 31 March 2378,44043,1219,976131,537
At 31 March 2277,5109019,97288,383
9.Description of nature of transactions and balances with related parties
During the year the company made available loans to the directors. These loans are repayable on demand. At the year end the balance of these was £NIL (2022: £149,039).
10.Stocks

2023

2022

££
Other stocks19,55019,550
Total19,55019,550
11.Debtors

2023

2022

££
Trade debtors / trade receivables39,28929,665
Amounts owed by group undertakings151,27230,983
Other debtors-152,689
Total190,561213,337
12.Creditors within one year

2023

2022

££
Trade creditors / trade payables9,00147,386
Bank borrowings and overdrafts10,0009,960
Taxation and social security105,51179,974
Finance lease and HP contracts7,0057,005
Other creditors7,897-
Accrued liabilities and deferred income8,1004,500
Total147,514148,825
13.Creditors after one year

2023

2022

££
Bank borrowings and overdrafts21,66831,707
Other creditors24,77931,783
Total46,44763,490
14.Finance lease and HP contracts after one year

2023

2022

££
Finance lease and HP contracts24,77931,784
15.Provisions for liabilities

2023

2022

££
Net deferred tax liability (asset)24,99216,793
Total24,99216,793